FOLFIRI + FOLFOX4 + talaporfin sodium

This is a combination regimen consisting of two established chemotherapy protocols, FOLFIRI and FOLFOX4, together with talaporfin sodium. - **FOLFIRI** combines irinotecan (a topoisomerase I inhibitor), folinic acid (leucovorin, a vitamin B derivative that enhances the effect of fluorouracil), and fluorouracil (5-FU, an antimetabolite that inhibits DNA synthesis). It is primarily used for metastatic colorectal cancer and sometimes gastric cancer[6][8]. - **FOLFOX4** consists of oxaliplatin (a platinum-based DNA crosslinker), folinic acid, and fluorouracil. It is also used in advanced colorectal cancer[1][7]. - **Talaporfin sodium** is a photosensitizer used in photodynamic therapy for certain cancers; it generates reactive oxygen species upon activation by specific wavelengths of light to induce tumor cell death. The combination aims to leverage multiple mechanisms—cytotoxicity from chemotherapeutics plus targeted photodynamic effects—to enhance anti-tumor efficacy. This regimen would be considered highly experimental as there are no standard protocols or published clinical trials combining all three components together.